Farmaci innovativi e sostenibilità
The recent availability of innovative, costly cancer drugs has prompted the search for a sustainable health economics model that would allow universal access to treatment coupled with long-term viability of the national health system. The huge R&D investment and the relatively short life of d...
Main Author: | Paolo Bonaretti |
---|---|
Format: | Article |
Language: | English |
Published: |
AboutScience Srl
2016-09-01
|
Series: | Global & Regional Health Technology Assessment |
Subjects: | |
Online Access: | https://journals.aboutscience.eu/index.php/grhta/article/view/307 |
Similar Items
-
Big Data and Pharmaceutical Industry: Applications and Priorities
by: Mohammad Hossein Ronaghi, et al.
Published: (2023-12-01) -
Comparison of the Effects of Public and Private Health Expenditures on the Health Status: a Panel Data Analysis in Eastern Mediterranean Countries
by: Enayatollah Homaie Rad, et al.
Published: (2013-01-01) -
Trends in pharmaceutical expenditure in the Taiwan National Health Insurance database at different hospital levels
by: Ching-Hu Chung
Published: (2022-12-01) -
Drugs with the highest drug expenditure in the Republic of Serbia
by: Milijašević Boris Ž., et al.
Published: (2023-01-01) -
Health care expenses impact on the disability-adjusted life years in non-communicable diseases in the European Union
by: Margarida Torres, et al.
Published: (2024-04-01)